Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year High – Still a Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $107.99 and last traded at $101.00, with a volume of 837649 shares changing hands. The stock had previously closed at $105.60.

Wall Street Analyst Weigh In

Several brokerages have commented on DNTH. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush lifted their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Stock Performance

The firm has a fifty day moving average of $89.98 and a 200-day moving average of $75.29. The stock has a market capitalization of $5.62 billion, a price-to-earnings ratio of -24.88 and a beta of 1.20.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, analysts predict that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insider Buying and Selling

In related news, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the sale, the senior vice president directly owned 30,000 shares of the company’s stock, valued at $2,424,000. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 87,779 shares of company stock valued at $7,985,235. Corporate insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics in the 2nd quarter worth $27,000. First Horizon Corp purchased a new stake in shares of Dianthus Therapeutics during the first quarter worth about $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $40,000. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics in the third quarter worth about $64,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.